Jpmorgan Chase & CO Atai Life Sciences N.V. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 17,924 shares of ATAI stock, worth $20,433. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,924

Previous 36,676 51.13%

Holding current value

$20,433

Previous $72,000 68.06%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.27 - $2.6 $23,815 - $48,755	-18,752 Reduced 51.13%	17,924 $23,000
Q1 2024 May 10, 2024	SELL	$1.5 - $2.19 $422,007 - $616,130	-281,338 Reduced 88.47%	36,676 $72,000
Q4 2023 Feb 12, 2024	BUY	$1.04 - $1.55 $185,260 - $276,109	178,135 Added 127.35%	318,014 $448,000
Q3 2023 Nov 14, 2023	BUY	$1.27 - $2.28 $62,958 - $113,028	49,574 Added 54.9%	139,879 $180,000
Q2 2023 Aug 11, 2023	BUY	$1.44 - $2.19 $119,845 - $182,264	83,226 Added 1175.67%	90,305 $155,000
Q1 2023 May 11, 2023	SELL	$1.17 - $2.7 $15,632 - $36,074	-13,361 Reduced 65.37%	7,079 $12,000
Q4 2022 Feb 13, 2023	BUY	$2.38 - $3.55 $20,579 - $30,696	8,647 Added 73.32%	20,440 $55,000
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $10,556 - $16,372	3,362 Added 39.88%	11,793 $39,000
Q2 2022 Aug 11, 2022	SELL	$3.03 - $5.32 $33,502 - $58,823	-11,057 Reduced 56.74%	8,431 $31,000
Q1 2022 May 11, 2022	BUY	$4.66 - $7.66 $24,963 - $41,034	5,357 Added 37.91%	19,488 $99,000
Q4 2021 Feb 10, 2022	BUY	$6.82 - $17.8 $96,373 - $251,531	14,131 New	14,131 $108,000

Others Institutions Holding ATAI

# of Institutions

Shares Held

12.8M

Call Options Held

9.2K

Put Options Held

118K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $189M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Atai Life Sciences N.V. Transaction History